Skip to main
NUVL
NUVL logo

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc., as a clinical-stage biopharmaceutical company, is advancing small molecule therapies specifically designed to target clinically validated kinase targets for cancer treatment, focusing on significant areas such as ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). The company has demonstrated strong and durable CNS activity with its candidates, particularly highlighting a favorable safety profile from a large patient cohort, which suggests the potential for substantial market uptake following anticipated drug approvals. With recent insights indicating an expanding physician willingness to adopt advanced therapies, coupled with substantial total addressable market estimates for their pipeline candidates, the fundamentals support a positive outlook for Nuvalent's growth trajectory.

Bears say

Nuvalent Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential for disappointing clinical results from its lead product candidates, NVL-520 and NVL-655. These disappointing outcomes could lead to a downward reassessment of market penetration, increased discount rates, and extended timelines for approval or even failure to gain approval. Additionally, the threat from competitive products and challenges related to regulatory and reimbursement processes further compound the company's uncertainties and may adversely impact its commercial viability.

Nuvalent (NUVL) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 12 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.